SGLT inhibition and euglycaemic diabetic ketoacidosis

被引:66
作者
Hine, Julia [1 ]
Paterson, Heather [1 ]
Abrol, Esha [1 ]
Russell-Jones, David [1 ]
Herring, Roselle [1 ]
机构
[1] Royal Surrey Cty Hosp, Dept Endocrinol & Diabet, Cedar Ctr, Guildford GU2 7XX, Surrey, England
关键词
D O I
10.1016/S2213-8587(15)00204-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:503 / 504
页数:3
相关论文
共 7 条
[1]   Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient [J].
Bell, David S. H. .
CASE REPORTS IN ENDOCRINOLOGY, 2015, 2015
[2]   SGLT inhibition in patients with type 1 diabetes [J].
Dehn, Clayton A. .
LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (07) :539-539
[3]   Diabetes mellitus secondary to pancreatic diseases (Type 3c) - Are we neglecting an important disease? [J].
Ewald, Nils ;
Bretzel, Reinhard G. .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2013, 24 (03) :203-206
[4]   Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study [J].
Henry, Robert R. ;
Rosenstock, Julio ;
Edelman, Steven ;
Mudaliar, Sunder ;
Chalamandaris, Alexandros-Georgios ;
Kasichayanula, Sreeneeranj ;
Bogle, Allyson ;
Iqbal, Nayyar ;
List, James ;
Griffen, Steven C. .
DIABETES CARE, 2015, 38 (03) :412-419
[5]   Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes [J].
Lamos, Elizabeth M. ;
Younk, Lisa M. ;
Davis, Stephen N. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (06) :875-882
[6]  
National Institute for Health and Clinical Excellence, 2013, NICE TECHN APPR TA28
[7]   Sodium- Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open- Label Proof- ofConcept Trial [J].
Perkins, Bruce A. ;
Cherney, David Z. I. ;
Partridge, Helen ;
Soleymanlou, Nima ;
Tschirhart, Holly ;
Zinman, Bernard ;
Fagan, Nora M. ;
Kaspers, Stefan ;
Woerle, Hans-Juergen ;
Broedl, Uli C. ;
Johansen, Odd-Erik .
DIABETES CARE, 2014, 37 (05) :1480-1483